Molecular diagnosis of human papillomavirus in the development of cervical cancer

Salud Publica de Mexico

Volumn 51, Issue SUPPL.3, 2009, Pages

  Gutiérrez Xicoténcatl, Lourdes ^a   Plett Torres, Tanya ^a   Madrid González, Claudia L ^a   Madrid Marina, Vicente ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Diagnosis; Human papillomavirus; Uterine cerival neoplasms

Indexed keywords

DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; IMMUNOLOGICAL PROCEDURES; MICROBIOLOGY; PAPILLOMAVIRUS INFECTION; REVIEW; UTERINE CERVIX TUMOR;

FEMALE; HUMANS; IMMUNOLOGIC TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 77957004141     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.1590/S0036-36342009000900014     Document Type: Article

References (103)

1. Eluf-Neto J, Nascimento CM. Cervical cancer in Latin America. Semin Oncol 2001;28(2):188-197.
2. Blumenthal PD, Ringers P, McIntosh N, Graffikin L. Innovative approaches to cervical cancer prevention. Medscape Womens Health 2001;6:1.
3. McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, Cokkinides V, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007;57(4):190-205.
4. Tapia-Conyer R, Kuri-Morales P, Macías-Martínez CG. Registro Histopatológico de Neoplasias en México. Mexico: Dirección General de Epidemiología, Secretaría de Salud, 2000.
5. Flores Y, Keerti S, Lazcano-Ponce E, Hernandez M, Bishai D, Ferris DG et al. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study. Salud Publica Mex 2002;44:335-344.
6. Lazcano-Ponce E, Alonso P, Ruiz-Moreno JA, Hernández-Avila M. Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development. Salud Publica Mex 2003;45 suppl 3:S449-S462.
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Patol 1999;189:12-19.
8. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265.
9. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
10. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999;9(6):423-430.
11. Chow LT, Broker TR. In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Clin Dermatol 1997;15(2):217-227.
12. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of Papillomaviruses. Virol 2004;324:17-27.
13. zur Hausen H. Papillomaviruses in human cancers. In: Infectious causes of cancer: Targets for intervention. Ed. Goedert JJ. USA:Humana Press, 2000:245-261.
14. zur Hausen H. Roots and perspectives of contemporary papillomavirus research. J. Cancer Res Clin Oncol 1996;122:3-13.
15. Beutner KR, Tyring S. Human papillomavirus and human disease. Am J Med 1997;102(5A):9-15.
16. García-Carrancá A, Gariglio PV. Molecular aspects of human papillomaviruses and their relation to uterine cervix cancer. Rev Invest Clin 1993;45(1):85-92.
17. Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006;16(2):83-97.
18. Gaillard-R C, Breitburd F, Orth G. Human Papillomavirus type 1 E4 N-terminal ends has distinct cellular localizations when transiently expressed in vitro. J Virol 1992;66:816-823.
19. Roberts S, Ashmole I, Gibson LJ, Rookes SM, Barton GJ, Gallimore PH. Mutational analysis of Human Papillomavirus E4 proteins: Identification of structural features important in the formation of cytoplasmic E4/cytokeratin networks in epithelial cells. J Virol 1994;68:6432-6445.
20. Yasumoto S, Burkhardt AL, Doniger J, DiPaolo JA. Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J Virol 1986;57:572-577.
21. Pirisi L, Yasumoto S, Feller M, Doniger J, DiPaolo JA. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol 1987;61:1061-1066.
22. Dyson N, Guida P, Munger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 1992;66:6893-6902.
23. Werness BA, Levine AJ. Howley PM, Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-79.
24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990 63:1129-1136.
25. Mietz JA, Unger T, Huibregtse JM, Howley PM. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1992;11(13):5013-5020.
26. Leechanachai P, Banks L, Moreau F, Matlashewski G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992;7(1):19-25.
27. Bouvard V, Matlashewski G, Gu Z-M, Storey A, Banks L. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 1994;203:73-80.
28. Biswas C, Kell B, Mant C, Jewers RJ, Cason J, Muir P, et al. Detection of human papillomavirus type 16 early-gene transcription by reverse transcription-PCR is associated with abnormal cervical cytology. J Clin Microbiol 1997;35(6):1560-1564.
29. Denny LA, Wright TC Jr. Human papillomavirus testing and screening. Best Pract Res Clin Obstet Gynaecol 2005;19:501-515.
30. Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis Markers 2007; 23: 273-281.
31. Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005;32 suppl 1:S43-S51.
32. Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W, et al. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 2008;80:1264-1274.
33. Lörincz AT. Screening for cervical cancer: new alternatives and research. Salud Publica Mex 2003;45 suppl 3:S376-S387.
34. Gravitt PE, Peyton CN, Apple RJ, Wheeler CM. Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method. J Clin Microbiol 1998;36(10):3020-3027.
35. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40(3):779-787.
36. Schiffman MH. Validation of hybridization assays: correlation of filter in situ, dot blot and PCR with Southern blot. IARC Sci Publ 1992;119:169-179.
37. Nijhuis ER, Reesink-Peters N, Wisman GB, Nijman HW, van Zanden J, Volders H, et al. An overview of innovative techniques to improve cervical cancer screening. Cell Oncol 2006;28(5-6):233-246.
38. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008;46(1):109-117.
39. Sabol I, Salakova M, Smahelova J, Pawlita M, Schmitt M, Gasperov NM, et al. Evaluation of different techniques for identification of human papillomavirus types of low prevalence. J Clin Microbiol 2008;46(5):1606-1613.
40. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37(8):2508-2517.
41. Melchers WJ, Bakkers JM, Wang J, de Wilde PC, Boonstra H, Quint WG, et al. Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am J Pathol 1999;155(5):1473-1478.
42. Quint WG, Scholte G, van Doorn LJ, Kleter B, Smits PH, Lindeman J. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF (10) PCR and HPV genotyping. J Pathol 2001;194:51-58.
43. Coutlée F, Gravitt P, Richardson H, Hankins C, Franco E, Lapointe N, et al. Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. The Canadian Women's HIV study group. J Clin Microbiol 1999;37(6):1852-1857.
44. Vernon SD, Unger ER, Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol 2000;38(2):651-655.
45. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38(1):357-361.
46. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001;91(3):412-420.
47. Klaassen CH, Prinsen CF, de Valk HA, Horrevorts AM, Jeunink MA, Thunnissen FB. DNA microarray format for detection and subtyping of human papillomavirus. J Clin Microbiol 2004;42(5):2152-2160.
48. Park TW, Zivanovic O, Theuerkauf I, Dürkop B, Hernando JJ, Simon M, et al. The diagnostic utility of human papillomavirus-testing in combination with immunohistochemistry in advanced gynaecologic pelvic tumours: a new diagnostic approach. Int J Oncol 2004;24(4):829-836.
49. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265(4):472-477.
50. Luft F, Klaes R, Nees M, Dürst M, Heilmann V, Melsheimer P, et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer 2001;92(1):9-17.
51. De Marco L, Gillio-Tos A, Bonello L, Ghisetti V, Ronco G, Merletti F. Detection of human papillomavirus type 16 integration in pre-neoplastic cervical lesions and confirmation by DIPS-PCR and sequencing. J Clin Virol 2007;38(1):7-13.
52. Jochmus-Kudielka I, Schneider A, Braun R, Kimming R, Koldovsky U, Schneweis KE, et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 1989;81:1698-1704
53. Jenison SA, Yu XP, Valentine JM, Koutsky LA, Christiansen AE, Beckmann AM, et al. Evidence of prevalent genital-type human papillomavirus infections in adults and children. J Infect Dis 1990;162(1):60-69.
54. Köchel HG, Sievert K, Monazahian M, Mittlestäd-Deterding A, Teichmann A, Thomssen R. Antibodies to human papillomavirus type-16 in human sera as reveled by the use of prokaryotically expressed viral gene products. Virology 1991;182:644-654.
55. Mandelson MT, Jenison SA, Sherman KJ, Valentine JM, McKnight B, Daling JR, et al. The association of human papillomavirus antibodies with cervical cancer risk. Cancer Epidemiol Biomarkers Prev 1992;1(4):281-286.
56. Ghosh AK, Smith NK, Stacey SN, Glew SS, Connor ME, Arrand JR, et al. Serological responses to HPV16 in cervical dysplasia and neoplasia: correlation of antibodies to E6 with cervical cancer. Int J Cancer 1993;53:591-596.
57. Dillner J. Mapping of linear epitopes of human papillomavirus type 16: the E1, E2, E4, E5, E6 and E7 open reading frames. Int J Cancer 1990;46(4):703-711.
58. Müller M, Gausepohl H, de MartynoffG, Frank R, Brasseur R, Gissmann L. Identification of seroreactive regions of the human papillomavirus type 16 protein E4, E6, E7 and L1. J Gen Virol 1990;71 (Pt 11):2709-2717.
59. Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Muñoz N, Shah KV. Serologic response in human papillomavirus-associated invasive cervical cancer. Int J Cancer 1993;55(5):780-784.
60. Nindl I, Benitez-Bribiesca L, Berumen J, Farmanara N, Fisher S, Gross G, et al. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients. Arch Virol 1994;137(3-4):341-353.
61. Sun Y, Shah KV, Müller M, Muñoz N, Bosch XF, Viscidi RP. Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins. J Clin Microbiol 1994;32(9):2216-2220.
62. Müller M, Viscidi RP, Ulken V, Bavinck JN, Hill PM, Fisher SG, et al. Antibodies to the E4, E6, and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated diseases and in the normal population. J Invest Dermatol 1995;104(1):138-141.
63. Dax, EM, Arnott A. Advances in laboratory testing for HIV. Pathology 2004;36:551-560.
64. Constantine, NT, Zink H. HIV testing technologies after two decades of evolution. Indian J Med Res 2005;121:519-538.
65. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci 1979;76:4350-4354.
66. Köchel HG, Monazahian M, Sievert K, Hohne M, Thomssen C, Teichmann A, et al. Occurrence of antibodies of L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical-cancer patients and controls. Int J Cancer 1991;48:682-688.
67. Suchánková A, Ritterová L, Krcmár M, Krchnák V, Vágner J, Jochmus I, et al. Comparison of ELISA and Western blotting for human papillomavirus type 16 E7 antibody determination. J Gen Virol 1991;72:2577-2581.
68. Fujii T, Matsushima Y, Yajima M, Sugimura T, Terada M. Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients. Jpn J Cancer Res 1995;86:28-34.
69. Kanda T, Onda T, Zanma S, Yasugi T, Furuno A, Watanabe S, et al. Independent association of antibodies against HPV type 16 E1/E4 and E7 proteins with cervical cancer. Virol 1992;190:724-732.
70. Pedroza-Saavedra A, Cruz A, Esquivel F, De La Torre F, Berumen J, Gariglio P, et al. High prevalence of serum antibodies to Ras and type 16 E4 proteins of human papillomavirus in patients with precancerous lesions of the uterine cervix. Arch Virol 2000;145(3):603-623.
71. Middleton K, Peh V, Southern S, Griffin H, Stolar K, Nakahara T, et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 2003;77(19):10186-10201.
72. Jenison SA, Yu XP, Valentine JM, Galloway DA. Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope. J Virol 1989;63(2):809-818.
73. Di Lonardo A, Campo MS, Venuti A, Marcante ML. Brief report: antibody response to E6, E7, and L1 proteins of human papillomavirus 16 in an Italian population. J Med Virol 1994;43(4):357-361.
74. Zhou J, Sun XY, Davies H, Crawford L, Park D, Frazer IH. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology 1992;189(2):592-599.
75. Xu YF, Zhang YQ, Xu XM, Song GX. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch Virol 2006;151(11):2133-2148.
76. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185(1):251-257.
77. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86(7):494-499.
78. Hofmann KJ, Neeper MP, Markus HZ, Brown DR, Müller M, Jansen KU. Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. J Gen Virol 1996;77(Pt 3):465-468.
79. Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10(2):101-106.
80. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003;89(7):1248-1254.
81. Bontkes HJ, de Gruijl TD, Walboomers JM, Schiller JT, Dillner J, Helmerhorst TJ, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999;80 (Pt 2):409-417.
82. Dillner J, Lenner P, Lehtinen M, Eklund C, Heino P, Wiklund F, et al. A population-based seroepidemiological study of cervical cancer. Cancer Res. 1994;54(1):134-141.
83. Veress G, Kónya J, Csiky-Mészáros T, Czeglédy J, Gergely L. Human papillomavirus DNA and anti-HPV secretory IgA antibodies in cytologically normal cervical specimens. J Med Virol 1994;43(2):201-207.
84. Marais D, Rose RC, Williamson AL. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa. J Med Virol 1997;51(2):126-131.
85. Crum CP, Barber S, Symbula M, Snyder K, Saleh AM, Roche JK. Coexpression of the human papillomavirus type 16 E4 and L1 open reading frames in early cervical neoplasia. Virology 1990;178(1):238-246.
86. Snyder KA, Barber SR, Symbula M, Taylor PT, Crum CP, Roche JK. Binding by immunoglobulin to the HPV-16-derived proteins L1 and E4 in cervical secretions of women with HPV-related cervical disease. Cancer Res 1991;51(16):4423-4429.
87. Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, Gallee MP, Hart AA, et al. Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. Cancer 1994;74(8):2307-2313.
88. Vazquez-Corzo S, Trejo-Becerril C, Cruz-Valdez A, Hernandez-Nevarez P, Esquivel-Guadarrama R, Gutierrez-Xicotencatl L. Association between anti-Ras and anti-HPV16 E4/E7 with intraepihelial cervical lesions. Rev Salud Pub Mex 2003;45:335-345. Available at: http://www.insp.mx/salud/45/eng/i455_1.pdf.
89. Bleul C, Müller M, Frank R, Gausepohl H, Koldovsky U, Mgaya HN, et al. Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. J Clin Microbiol 1991;29(8):1579-1588.
90. Müller M, Viscidi RP, Sun Y, Guerrero E, Hill PM, Shah F, et al. Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology 1992;187(2):508-514.
91. Krchnák V, Vágner J, Suchánková A, Krcmár M, Ritterová L, Vonka V. Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J Gen Virol 1990;71(Pt 11):2719-2724.
92. Dillner J. Disappearance of antibodies to HPV 16 E7 after treatment for cervical cancer. Lancet 1993;341(8860):1594.
93. Hamsiková E, Novák J, Hofmannová V, Munoz N, Bosch FX, de Sanjosé S. Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. J Infect Dis 1994;170(6):1424-1431.
94. de Sanjosé S, Bosch FX, Muñoz N, Tafur L, Gili M, Izarzugaza I, et al. Socioeconomic differences in cervical cancer: two case-control studies in Colombia and Spain. Am J Public Health 1996;86(11):1532-1538.
95. Fisher SG, Benitez-Bribiesca L, Nindl I, Stockfleth E, Muller M, Wolf H, et al. The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer. Gynecol Oncol 1996;61(1):73-78.
96. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997;71(3):2463-2472.
97. Muñoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000;19(1-2):1-5.
98. de Roda-Husman AM, Walboomers JM, Hopman E, Bleker OP, Helmerhorst TM, Rozendaal L, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol 1995;46(2):97-102.
99. Moscicki AB. HPV infections in adolescents. Dis Markers 2007; 23(4): 229-234.
100. Poljak M, Brencic A, Seme K, Vince A, Marin IJ. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J Clin Microbiol 1999;37(3):796-797.
101. Clavel C, Masure M, Putaud I, Thomas K, Bory JP, Gabriel R, et al. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol 1998;51(10):737-740.
102. Monsonego J, Bohbot JM, Pollini G, Krawec C, Vincent C, Merignargues I, et al. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 2005;99(1):160-168.